Valeri et al

2	Extracellular Matrix Abnormalities in the Hippocampus of Subjects with Substance Use
3	Disorder
4	Jake Valeri <sup>a,b</sup> , Charlotte Stiplosek <sup>a</sup> , Sinead M. O'Donovan <sup>c</sup> , David Sinclair <sup>c</sup> , Kathleen Grant <sup>d</sup> ,
5	Ratna Bollavarapu <sup>b</sup> , Donna M. Platt <sup>a,b</sup> , Craig A. Stockmeier <sup>a,b</sup> , Barbara Gisabella <sup>a,b</sup> , Harry
6	Pantazopoulos <sup>a,b</sup>
-	
7	a) Department of Psychiatry and Human Behavior, University of Mississippi Medical Center,
8	Jackson, MS
9	b) Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS
10	c) Department of Neuroscience, University of Toledo, Toledo, OH
11	d) Oregon Primate Research Center, Hillsboro, OR
12	
13	
14	
15	
16	
10	
17	
18	Address for correspondence:
19	Harry Pantazopoulos, PhD
20	Department of Psychiatry and Human Behavior
21	University of Mississippi School of Medicine
22	TRC 407
23	2500 North State St
24	Jackson, MS 39216, USA
25	Phone: (601) 815-7983
26	E-mail: cpantazopoulos@umc.edu

## Valeri et al

## 27 ABSTRACT

28 Contextual triggers are significant factors contributing to relapse in substance use disorders (SUD). 29 Emerging evidence points to a critical role of extracellular matrix (ECM) molecules as mediators of reward 30 memories. Chondroitin sulfate proteoglycans (CSPGs) are a subset of ECM molecules that form 31 perineuronal nets (PNN) around inhibitory neurons. PNNs restrict synaptic connections and help maintain 32 synapses. Rodent models suggest that modulation of PNNs may strengthen contextual reward memories 33 in SUD. However, there is currently a lack of information regarding PNNs in the hippocampus of people 34 with SUD as well as how comorbidity with major depressive disorder (MDD) may affect PNNs. We used 35 postmortem hippocampal tissues from cohorts of human and nonhuman primates with or without chronic 36 alcohol use to test the hypothesis that PNNs are increased in subjects with SUD. We used histochemical 37 labeling and quantitative microscopy to examine PNNs, and gRT-PCR to examine gene expression for 38 ECM molecules, synaptic markers and related markers. We identified increased densities of PNNs and 39 CSPG-labeled glial cells in SUD, coinciding with decreased expression of the ECM protease matrix 40 metalloproteinase 9 (Mmp9), and increased expression for the excitatory synaptic marker vesicle 41 associated membrane protein 2 (Vamp2). Similar increases in PNNs were observed in monkeys with 42 chronic alcohol self-administration. Subjects with MDD displayed changes opposite to SUD, and subjects 43 with SUD and comorbid MDD had minimal changes in any of the outcome measures examined. Our findings 44 demonstrate that PNNs are increased in SUD, possibly contributing to stabilizing contextual reward 45 memories as suggested by preclinical studies. Our results also point to a previously unsuspected role for 46 CSPG expression in glial cells in SUD. Evidence for increased hippocampal PNNs in SUD suggests that targeting PNNs to weaken contextual reward memories is a promising therapeutic approach for SUD, 47 48 however comorbidity with MDD is a significant consideration.

- 49
- 50
- 51

## Valeri et al

# 53 **INTRODUCTION**

Substance use disorders (SUD) are a group of psychiatric disorders with substantially 54 55 increased risk of mortality and severe socioeconomic burden affecting approximately 7 % of people in the United States annually <sup>1, 2</sup>. SUDs impose a substantial burden of morbidity and 56 57 mortality, exacerbated by persistently high rates of relapse and treatment failure <sup>3</sup>. Contextual cues associated with drug use are a critical factor contributing to relapse in individuals with SUD 58 and highlight the strength of memory circuits associated with reward processing <sup>3-7</sup>. A growing 59 number of studies indicate a critical role of extracellular matrix molecules (ECM) in the regulation 60 of reward memories <sup>8-17</sup> (for reviews see <sup>18, 19</sup>). Recent gene expression profiling studies 61 demonstrate altered expression of pathways involved in ECM regulation in the dorsolateral 62 prefrontal cortex and nucleus accumbens of subjects with opioid use disorder (OUD) <sup>12, 20</sup> as well 63 as in preclinical models of OUD <sup>20</sup>. 64

Preclinical studies of cocaine, alcohol or opioid use demonstrate that alteration of specialized 65 ECM structures called perineuronal nets (PNN) represent a key feature underlying reward 66 memory in SUDs<sup>8, 9, 17, 21-24</sup>. PNNs are ECM structures that envelop populations of fast-firing 67 inhibitory neurons, stabilizing synapses on those neurons and restricting synaptic plasticity <sup>16, 22,</sup> 68 <sup>25, 26</sup>. During acquisition of drug memories, endogenous proteases including matrix 69 70 metalloproteases (MMPs) degrade PNN components to allow for formation of new synapses associated with reward memories. <sup>11, 27-30</sup>. Chronic drug use resulting in prolonged re-activation of 71 72 memory circuits results in enhancement of PNN components in the prefrontal cortex and insular cortex, stronger than at baseline, which stabilizes reward-associated synapses 9, 23, 24, 31-33 and 73 74 may contribute to context-induced relapse <sup>11, 27-30</sup>. Evidence that intracerebral injection of a pharmacological MMP inhibitor significantly weakens cocaine reward memories provides further 75 support for this hypothesis <sup>10</sup>. The hippocampus is at the center of neurocircuitry involved in 76 reward memory processing <sup>34</sup>. Specifically, accumulating evidence suggests that hippocampal 77

#### Valeri et al

78 sector CA1 is involved in integrating dopamine reward signaling with contextual memories and in regulating reward expectation and extinction <sup>35-37</sup>. CA1 neurons receive dopaminergic projections 79 from the ventral tegmental area and encode reward-associated spatial memories <sup>37, 38</sup>. CA1 spatial 80 maps are modified by reward expectation and by inhibitory control of excitatory neurons encoding 81 82 these maps <sup>37, 38</sup>. Inhibitory neurons in CA1 are often surround by PNNs, and alterations of hippocampal PNNs impact several neurotransmitter systems associated with reward processing. 83 For example, PNN degradation alters firing rate of inhibitory parvalbumin (PVB) neurons <sup>39</sup>, as 84 well as NMDAR/AMPAR trafficking <sup>40</sup> and hippocampal dopamine transmission <sup>41</sup>. 85

Despite this evidence, there is a lack of information regarding PNNs in the hippocampus of 86 subjects with SUD, limiting the translatability of preclinical findings and the development of ECM-87 based therapies for context-induced relapse. Furthermore, subjects with SUD often have 88 89 comorbid substance use and a high degree of comorbidity with major depressive disorder (MDD) 90 <sup>42</sup>. These features are challenging to capture in preclinical models, potentially limiting translatability. We used a cohort of human postmortem samples from subjects with SUD with or 91 without comorbid MDD to test the hypothesis that numerical density of PNNs is increased in sector 92 CA1 of subjects with SUD, accompanied by altered expression of genes related to ECM 93 94 degradation and biosynthesis, synaptic regulation, and PVB expression. This cohort includes retrospective clinical assessments, toxicology reports, history of substance use and medication 95 history, allowing for testing of several of the features inherent in the population with SUD. Subjects 96 with comorbid SUD and MDD, and subjects with MDD without SUD were included to examine the 97 98 potential effects of comorbid MDD on ECM pathology in SUD. Furthermore, we used a collection of postmortem hippocampus samples from rhesus monkeys with or without chronic alcohol self-99 100 administration to examine the direct cause and effect on PNNs of the most common drug of abuse present across all our subjects with SUD. 101

Valeri et al

# 103 MATERIALS AND METHODS

# 104 **Postmortem brain samples**

105 Human subjects for brightfield microscopy and RNA studies

Fresh frozen blocks containing the hippocampus from subjects with SUD (n=20), SUD and comorbid MDD (n=24), MDD (n=20), and psychiatrically normal controls (n=20) were provided by the UMMC Postmortem Brain Core (Table 1, Cohort A). Details are described in our previous report <sup>43</sup> and in the Supplemental Materials.

110 Psychiatric control subjects for confocal imaging

Paraformaldehyde fixed free-floating samples containing the hippocampus were obtained from a 111 separate cohort of three control subjects from the Harvard Brain Tissue Resource Center (Table 112 1, Cohort B), as fresh frozen tissue is not suitable for reliable immunohistochemical labeling for 113 parvalbumin and synaptic markers. Two psychiatrists determined the absence of DSM-IV 114 115 diagnoses based on the review of a questionnaire filled out by legal next of kin and a review of all 116 available medical records. Control cases had sufficient information from legally-defined next of 117 kin and medical records to rule out major medical, neurologic, and psychiatric conditions. All 118 brains underwent a complete neuropathological exam and cases with histopathological abnormalities were excluded from this study. 119

120 Rhesus macaque subjects

Fresh frozen hippocampus samples from adult male rhesus macaques (*Macaca mulatta*) were obtained from the Monkey Alcohol Tissue Research Resource (MATRR) Cohort 5 (Table 1, Cohort C). Details regarding these subjects are available at <u>www.matrr.com</u> and described in the Supplemental Materials. Subjects were allowed to freely self-administer alcohol for 22 h daily for one year.

Valeri et al

# 126 Tissue collection and processing

## 127 Fresh frozen postmortem samples (Cohorts A&C)

128 Coronal serial sections (14 μm) were obtained from fresh frozen postmortem hippocampal blocks.

129 Blocks were dissected and rapidly frozen in 2-methylbutane and on dry ice without fixation and

130 kept in dry ice before permanent storage at -80 °C. Blocks were sectioned using a Leica CM3050S

131 cryostat.

132 Paraformaldehyde fixed control subjects (Cohort B)

133 Tissue blocks containing the hippocampus were processed as described previously <sup>44</sup>.

# 134 Histochemical/immunocytochemical labeling, imaging, and quantification procedures

#### 135 Brightfield microscopy

Fresh-frozen, slide-mounted medial hippocampal cryosections from human subjects and rhesus 136 macaque subjects (3-5 sections per subject) were post-fixed for 30 minutes in 4% 137 paraformaldehyde, followed by 1-hour incubation in 2% bovine serum albumin (BSA), and 138 139 overnight incubation in biotinylated Wisteria floribunda agglutinin (WFA) lectin (1:500, catalog #B-1355, Vector Labs). WFA binds to non-sulfated N-acetyl-D-galactosamine residues on the 140 terminal ends of CSPGs <sup>45</sup>. The following day, tissue was incubated in streptavidin horseradish 141 peroxidase (1:5000 µl, Zymed, San Francisco, CA) for four hours, followed by a 20-minute 142 incubation in 3'3-diaminobenzidine with nickel sulfate hexahydrate and H<sub>2</sub>O<sub>2</sub>. Tissue was 143 dehydrated through an ethanol and xylene series, followed by histological labeling with Methyl 144 145 Green (catalog #H-3402, Vector Labs). Sections were coverslipped and coded for blinded quantitative analysis. All sections included in the study were processed simultaneously to avoid 146 procedural differences. Quantification was performed using an Olympus BX61 microscope and 147 WFA-labeled PNNs were distinguished from WFA+ glial cells based on morphology. Each 148

Valeri et al

- anatomical subdivision of the hippocampus was traced for an area measurement using a 20X
   objective, and WFA-labeled elements were quantified on 40X magnification using Stereo-
- 151 Investigator v11.
- 152 Immunofluorescence and Imaging
- 153 Immunofluorescence for VAMP2-PVB-WFA and for GFAP-WFA were conducted as described
- 154 previously <sup>46, 47</sup> and in the Supplemental Materials.
- 155 Quantitative polymerase chain reaction
- qPCR was conducted as described previously <sup>43, 48</sup> and in the Supplemental Materials. The
   primers used are listed in Supplemental Table 21.

# 158 Statistical Analysis

Numerical densities of microscopy measures were calculated as described in our previous studies 159 160 <sup>49 46, 47</sup>. The goal of our study was to test for differences in PNN densities in CA1 and hippocampal 161 gene expression of ECM and synaptic markers between diagnosis groups. Analysis of WFA-glial 162 densities was focused on the DG and CA4 areas where these cells are primarily distributed in the hippocampus in our current study and our previous report <sup>49</sup>. Diagnosis groups with comorbid 163 SUD/MDD and MDD were included to test for potential effects of comorbid depression on findings 164 in SUD. Exploratory analysis was conducted on microscopy measures of PNNs and WFA-glia on 165 additional hippocampal sectors. Differences between groups relative to the main outcome 166 167 measures were assessed for statistical significance using stepwise linear regression analysis of 168 covariance (ANCOVA) using JMP Pro v16.1.0 (SAS Institute Inc., Cary, NC). Logarithmic transformation was applied to values when not normally distributed. Potential confounding 169 variables (Table 1 and Supplementary Tables 5-20) were tested systematically for their effects on 170 main outcome measures and included in the model if they significantly improved goodness-of-fit. 171 172 Covariates found to significantly affect outcome measures are reported. Subjects with SUD,

Valeri et al

subjects with SUD/MDD, and subjects with MDD were first compared separately with psychiatrically-normal controls. Subsequently, the four groups were considered together to test for differences between diagnostic groups and Bonferroni correction applied for multiple comparisons.

177 **RESULTS** 

# 178 Altered PNN and WFA-glia densities in subjects with SUD, MDD, and comorbid SUD/MDD

Numerical densities of PNNs were significantly increased in CA1 stratum oriens (SO) of subjects 179 with SUD (p < 0.007; adjusted for significant effects of PMI and cocaine history). (Figure 1A-E), 180 where the majority of PNNs were distributed in sector CA1 (Control CA1 SO: 3.5 PNNs/mm<sup>2</sup>; 181 182 Control CA1 SP: 0.97 PNNs/mm<sup>2</sup>). Further analysis of additional hippocampal sectors revealed increased numerical densities of PNNs in CA2 SO (p < 0.03; adjusted for significant effects of 183 age), CA2 SP (p < 0.0001; adjusted for significant effects of cocaine history), CA3 SO (p < 0.01; 184 185 adjusted for significant effects of cocaine history), and CA4 (p < 0.007; adjusted for significant 186 effects of cocaine history) in subjects with SUD (Figure 1G, Table S1). History of cocaine use, which was a significant covariate across hippocampal subregions, was associated with decreased 187 PNNs in each of these regions (Figure S4D). No significant differences were found in the dentate 188 189 gyrus or the CA1 and CA3 SP layers. In subjects with MDD, we observed significantly decreased 190 numerical densities of PNNs in CA1 SO (p < 0.05; adjusted for significant effects of sex and calcium channel blockers) and CA1 SP (p < 0.02), increased PNNs in CA4 (p < 0.01; adjusted for 191 significant effects of anxiety disorder diagnoses), and no significant differences in other regions 192 of the hippocampus. The duration of depression positively correlated with PNN density in CA1 193 194 SO across subjects with SUD/MDD and MDD (Figure S1A). In subjects with comorbid SUD/MDD, we observed reduced numerical densities of PNNs in CA1 SP (p < 0.02; adjusted for significant 195 effects of substance abuse history and duration of MDD, Figure S1B), increased densities of 196 197 PNNs in CA2 SP (p < 0.01; adjusted for significant effects of SSRIs in the toxicology report and

Valeri et al

ZT time). No significant differences were observed in the other hippocampal subregions. Table
 S1 contains information for each hippocampus subregion, including p-values, F-ratios, adjusted
 least squares means, standard error, and significant covariates.

201 We observed WFA-labeled glial cells in addition to PNN labeling. WFA-glia in our current study 202 were shown to co-express the astrocyte marker glial fibrillary acidic protein (GFAP) (Figure S5) 203 and were morphologically similar to WFA-glia described our previous reports in the human medial temporal lobe <sup>46, 47</sup>. WFA-glial cells were distributed primarily in the dentate gyrus and CA4 areas, 204 205 with sparse expression in other hippocampal subregions (Figure 1H-K, N). In subjects with SUD, we observed significantly greater density of WFA-glia in CA4 (p < 0.002; adjusted for significant 206 effect of cocaine history), and in the dentate gyrus (p < 0.02; adjusted for significant effect of 207 cocaine history, Figure 1L). No other hippocampal subregions displayed statistically significant 208 209 differences in subjects with SUD. In subjects with MDD, we observed significantly increased 210 densities of WFA-glia in the dentate gyrus (p < 0.0001), CA3 SP (p < 0.0008; adjusted for a significant effect of antidepressants in last month of life), CA2 SP (p < 0.006; adjusted for a 211 significant effect of antidepressants in last month of life), and CA2 SO (p < 0.02). All other 212 hippocampal subregions lacked differences in subjects with MDD. In subjects with comorbid 213 SUD/MDD, we observed significantly decreased numerical densities of WFA-glia in the dentate 214 gyrus (p < 0.02; adjusted for significant effects of alcohol in the toxicology report and calcium 215 channel blockers), CA4 (p < 0.02; adjusted for a significant effect of alcohol in the toxicology 216 217 report), CA3 SP (p < 0.002; adjusted for significant effects of alcohol in the toxicology report and 218 race), CA2 SP (p < 0.004; adjusted for a significant effect of race), CA1 SP (p < 0.02; adjusted for significant effects of antipsychotics and alcohol in the toxicology report), and CA1 SO (p < 1219 220 0.02; adjusted for a significant effect of race) when compared to psychiatric control subjects. Table S2 contains information for each hippocampus subregion. No differences in hippocampal area 221

Valeri et al

222 measurements were detected between control subjects and any of the diagnosis groups 223 (Supplementary Table S4).

## 224 Gene expression of markers for cell populations associated with PNNs and WFA-glial cells

Parvalbumin. Neurons expressing parvalbumin (Pvb) mRNA represent the majority of neurons 225 surrounded by PNNs in the hippocampus <sup>49-51</sup>. Subjects with SUD had significantly greater gene 226 expression of Pvb compared to control subjects (Fig. 1F. Table S3: p <0.007: adjusted for a 227 228 significant effect of cocaine history). Subjects in the SUD group with cocaine in the blood at death 229 had significantly lower *Pvb* gene expression compared to subjects with SUD without cocaine in the blood at death (Supplemental Figure S4B). Pvb mRNA was also significantly greater in 230 231 subjects with comorbid SUD/MDD (p < 0.008), and subjects with MDD (p < 0.005) compared to control subjects (Fig. 1F, Table S3). 232

*Glial fibrillary acidic protein.* The astrocyte marker glial fibrillary acidic protein (Gfap) colocalized with astrocytes labeled by WFA (Figure S5), which is in line with previous reports from human postmortem studies <sup>46, 52</sup>. *Gfap* gene expression was significantly lower in the hippocampus of subjects with comorbid SUD/MDD (p < 0.02; adjusted for significant effects of SSRIs in last month of life which increases *Gfap*) (Fig. 1M, Table S3). No changes were detected in the SUD or MDD groups.

## 239 Altered expression of synaptic markers in the hippocampus of subjects with SUD

Synaptobrevin and Synapsin 1. Synaptobrevin (VAMP2) is an excitatory synaptic marker that contributes to the SNARE complex, allowing for fusion of vesicles to the cell membrane to facilitate neurotransmitter exocytosis and receptor trafficking <sup>53, 54</sup>. We examined VAMP2 as a step towards altered synaptic regulation in the hippocampus of subjects with SUD as suggested by extensive literature indicating altered synaptic regulation by chronic exposure to substances of abuse (for review see <sup>55</sup>). We first tested whether VAMP2 protein is located on PVB neurons and in PNNs,

Valeri et al

246 and observed VAMP2 protein on PVB neurons ensheathed by PNNs and enmeshed within the 247 PNN (Figure 2B-E). In subjects with SUD, Vamp2 mRNA was significantly increased (p < 0.04; adjusted for a significant effect of sleep quality). An increase in Vamp2 transcription was also 248 249 observed in subjects with MDD (p < 0.005; with significant effects of age, ZT time, and sleep 250 disturbance). No changes in Vamp2 expression were detected in subjects with comorbid SUD/MDD. We conducted similar analysis for the inhibitory presynaptic marker, synapsin 1 251 (Syn1). We observed spatial overlap of SYN1 protein with PVB interneurons coated by PNNs, 252 including SYN1 within PNNs (Figure 2G-J). In contrast to Vamp2, no significant differences were 253 254 observed for Syn1 gene expression in any of the diagnostic groups (Figure 2F).

# 255 Altered expression of ECM molecules in the hippocampus of subjects with SUD

*Matrix metalloproteinase 9 (Mmp9) and Cathepsin S (Ctss).* Significantly decreased expression of *Mmp9* was observed in subjects with SUD (Figure 3A: p < 0.04). Furthermore, *Ctss* mRNA was significantly decreased in subjects with SUD (Figure 3B, S4: p < 0.03; with significant effects of cocaine in the toxicology report), and increased in subjects with MDD (p < 0.04; adjusted for significant effects of alcohol use severity and ZT time). No significant changes were observed in subjects with comorbid SUD/MDD (Figure 3A-B).

Aggrecan and Chondroitin synthase 1. In subjects with SUD/MDD, we observed significantly increased aggrecan (*Acan*) (Figure 3C: p < 0.03), as well as chondroitin synthase 1 (*Chsy1*) mRNA (Figure 3D, S3B: p < 0.0001; with significant effects of duration of AUD and tissue pH). In subjects with SUD, a significant increase in *Chsy1* expression was detected (Figure 3C, S3: p < 0.04; with a significant effect of tissue pH), and no significant difference was observed for *Acan* (Figure 3D). No changes were observed in subjects with MDD for either *Acan* or *Chsy1* (Figure 3C&D).

## Valeri et al

# Increased numerical densities of perineuronal nets in the hippocampus of monkeys with chronic alcohol self-administration

We observed a significant increase of PNNs in the combined hippocampal subfields in rhesus monkeys with chronic alcohol self-administration (p < 0.03). Similar increases were observed in CA1 SO (Figure 4E; p < 0.04), CA3 SO (Figure 4E; p < 0.03), and CA3 SP (Figure 4E; p < 0.03). We also detected significantly increased numerical densities of WFA-labeled glia in the dentate gyrus granule cell layer (Fig. 4F; p < 0.04).

## 276 **DISCUSSION**

Our data represent, to our knowledge, the first evidence for increased PNN densities in 277 278 subjects with SUD and rhesus macaques with chronic alcohol self-administration. These findings link over a decade of evidence from preclinical models demonstrating increased PNNs in animals 279 with chronic drug use 9, 17, 23, 24, 32, 56-58 with evidence in subjects with SUD. Together with the 280 observed increased expression of the synaptic marker Vamp2 and the CSPG synthesis molecule 281 282 Chsv1, this suggests that enhanced PNN composition may aid in stabilizing contextual rewardassociated synapses in the CA1 hippocampus of individuals with SUD. CA1 hippocampal neurons 283 284 receive dopaminergic projections from the ventral tegmental area and encode reward-related spatial memories <sup>37, 38</sup>. These CA1 spatial maps are modulated by local inhibitory control of 285 286 excitatory neurons that encode the spatial map <sup>37, 38</sup>. Speculatively, increased PNNs in CA1 of subjects with SUD may contribute to selective inhibitory control of excitatory neurons to sustain 287 spatial maps involved in drug reward memories. Contextual memory processing may differ 288 289 between drugs of abuse, and preclinical studies report decreases or no change in PNN densities with some drug classes including chronic nicotine, cocaine or opioid exposure <sup>17, 21, 31</sup>. Our findings 290 represent hippocampal alterations in subjects with polysubstance use which consists of a 291 significant population of people seeking treatment for SUDs. Similar findings in nonhuman 292 primates with chronic alcohol use together with increased PNNs in preclinical models of cocaine 293

#### Valeri et al

294 suggests that increased PNN densities may be a shared feature in people with polysubstance use disorder which often includes alcohol use disorder <sup>9, 24, 32, 59, 60</sup>. Furthermore, decreased 295 expression of ECM proteolytic molecules indicates that changes in PNN densities are 296 accompanied by decreased ECM remodeling in chronic SUD. Increased expression of 297 298 parvalbumin, expressed by neurons that PNNs typically encapsulate, suggests increased feedforward inhibition of local excitatory pyramidal neurons by parvalbumin that may enhance 299 coherence of drug-associated neuronal ensembles. In contrast, decreased densities of PNNs in 300 subjects with MDD represent the first evidence for altered PNNs in the hippocampus of subjects 301 with MDD. Taken together, our findings support the hypothesis that increased PNNs may stabilize 302 contextual reward memories in subjects with SUD and thus may represent therapeutic targets for 303 context-induced relapse. Furthermore, decreased densities of PNNs in subjects with MDD and 304 lack of significant differences in subjects with comorbid SUD/MDD highlight the importance of 305 306 considering comorbid conditions for the neuropathology of SUD.

307

## 308 PNNs and ECM molecules in the Hippocampus of Subjects with Substance Use Disorder

Our findings support an increasing number of preclinical studies demonstrating that PNNs 309 stabilize reward memories <sup>8, 9, 16, 17, 22-24, 33</sup>. Furthermore, PNNs are involved in a wide range of 310 processes that can impact context-induced relapse including stabilization of synapses, receptor 311 trafficking, and regulation of interneuron activity <sup>25, 26, 39, 40, 61-67</sup>. Previous studies have implicated 312 each of these processes in SUD. For example, chronic substance use has been shown to elicit 313 downstream alteration of synapses and neurotransmitters including changes in dopamine 2 314 receptors (D2R) <sup>68</sup> as well as glutamatergic and GABAergic systems <sup>69, 70</sup>. SUDs are chronically 315 relapsing disorders which rely heavily on memory salience (i.e., cue responsiveness). PNNs 316 317 contribute to synaptic homeostasis through the stabilization of synapses and PVB interneuron-

#### Valeri et al

mediated excitatory/inhibitory balance <sup>71</sup>. Thus, PNNs may stabilize synapses involved in drug
 reward processes that contribute to context-induced relapse <sup>18</sup>.

320 The association of PVB interneurons with PNNs has been demonstrated in several brain areas, including the hippocampus <sup>49, 72-74</sup>. Hippocampal PVB neurons are predominantly located 321 322 in the SO layers of the CA regions. PVB neurons are involved in modulating glutamatergic neurons and hippocampal output to brain regions involved in reward processing <sup>75, 76</sup>. Increased 323 PVB expression is positively correlated with PNN labeling 77 and removal of PNNs with 324 chondroitinase ABC or antidepressants decreases PVB interneuron activity <sup>78</sup>. Increased 325 parvalbumin (PVB) expression in SUD may induce feedforward inhibition of local excitatory 326 neurons that enhances coherence of drug-specific neuronal ensembles <sup>79</sup>. Enhanced PNN 327 composition on PVB neurons may also contribute to increased PVB expression and downstream 328 329 consequences on excitatory/inhibitory balance which can result in altered activity of reward 330 circuits involved in reward prediction and impulsivity <sup>80, 81</sup>. Importantly, *Pvb* expression was significantly decreased in subjects with cocaine in their toxicology reports (Supplementary Figure 331 1G), suggesting that cocaine temporarily blunts PVB expression to disinhibit excitatory neurons 332 <sup>57</sup>. Furthermore, decreased ECM proteolytic gene expression (*Mmp9* and *Ctss*) in subjects with 333 334 SUD is in line with increased PNN densities in these subjects and with preclinical models of hippocampal MMP9 expression in alcohol use <sup>82</sup>, potentially suggesting hypofunction of PNN 335 proteolytic systems in SUD<sup>83</sup>. In our ANCOVA models, subjects with SUD who had cocaine in 336 their toxicology reports had greater expression of *Ctss* (Supplementary Figure 1H). Speculatively, 337 338 increased Ctss and decreased Pvb in subjects with cocaine in the toxicology report may indicate that cocaine temporally activates Ctss to temporarily degrade PNNs and decrease in Pvb 339 340 expression.

There is extensive evidence demonstrating a central role of the hippocampus for episodic memory processing <sup>84</sup>. Furthermore, the hippocampus has bi-directional connections with the

#### Valeri et al

amygdala that contribute to assigning emotional valence to contextual memories, which is crucial
in the long-term retention of drug memories <sup>85</sup>. Hippocampal connections with the ventral
tegmental area (VTA) are involved in regulating memory salience and reward predictions.
Hippocampal glutamatergic fibers from CA1 travel through the subiculum to basal forebrain
structures, and synapse onto VTA neurons which feed back to the hippocampus to release
dopamine <sup>80, 81</sup>. Thus, increased PNNs in the hippocampus of subjects with SUD can impact this
system and contribute to several aspects of reward memory circuits.

Our studies represent first description of increased numerical densities of WFA-glial cells in individuals with SUD. Despite previous evidence that WFA-glia colocalize with the astrocytic marker GFAP <sup>46, 47</sup>, we did not detect increased GFAP expression in subjects with SUD, suggesting that increases in WFA-glia do not reflect a broader astrogliosis process. Increased WFA-glia in the hippocampus may indicate increased CSPG production by glia contributing to increased PNNs in SUD.

356 We used a proximal specie, Macaca mulatta, with or without chronic alcohol use to test for specific effects of the most common drug in our cohort without the covariates inherent to cross-357 sectional human studies. Increased PNN densities and WFA-glia in rhesus monkeys with chronic 358 359 alcohol use provides support for our findings in human subjects. Furthermore, the ability of chronic 360 alcohol use alone to create these changes is intriguing and represents the first evidence for increased PNNs in the hippocampus of non-human primates in response to any drug of abuse. 361 The present findings also represent the first observation of WFA-labeled glia in the non-human 362 primate brain; to this point, they have only been reported in human subjects <sup>46, 49, 73</sup>. These WFA-363 364 glial cell increases may represent enhanced CSPG synthesis by astrocytes.

PNNs and ECM molecules in the Hippocampus of Subjects with Comorbid Substance Use
 Disorder and Major Depressive Disorder

#### Valeri et al

367 Subjects with comorbid SUD and MDD represent a significant population of people with SUD 368 and a bi-directional disorder where dysphoria can fuel the inclination to self-medicate. Alternatively, chronic drug use can contribute to mood disturbances <sup>86</sup>. Approximately one third 369 of patients with MDD also experience SUD, and conversely a substantial proportion of individuals 370 with SUD will experience MDD at some point during prognosis <sup>42, 87</sup>. This bi-directional comorbidity 371 contributes to a heightened risk of suicide and greater social and personal impairment <sup>88</sup>. Despite 372 this relationship, co-occurrence of MDD and SUD is not typically examined in postmortem brain 373 studies. Our results suggest MDD comorbidity is an important factor in studies of SUD. Inclusion 374 375 of subjects with MDD may either mask or amplify changes present in each disorder. Most of our outcome measures displayed opposing directionality between subjects with SUD and MDD. For 376 example, density of CA1 SO PNNs was significantly increased in SUD, decreased in MDD, and 377 unaltered in subjects with comorbid SUD/MDD. In comparison, a comorbid diagnosis of MDD 378 379 appeared to significantly amplify the existing increased expression of Chsv1 observed in subjects with SUD (Figure 3D). 380

Increased expression of *Chsy1* in SUD and subjects with SUD/MDD may suggest that increased biosynthesis of CSPGs by chronic drug use is enhanced by processes underlying MDD. Expression of the CSPG aggrecan, a major PNN component <sup>89</sup>, was increased in subjects with comorbid SUD/MDD. This may represent alterations in PNN composition that are not detected by standard WFA labeling.

386 PNNs and ECM molecules in the Hippocampus of Subjects with Major Depressive Disorder

A strength of our cohort was the ability to cross-examine the incidence of MDD comorbid with SUD as well as subjects with MDD only. While densities of PNNs were decreased in subjects with MDD (Fig. 1C), the duration of MDD positively correlated with densities of PNNs in CA1 SO (Supplementary Figure 1A). This is in line with preclinical evidence demonstrating that animals exposed to chronic social defeat display increased PNNs in the hippocampus <sup>90</sup>. Over time,

#### Valeri et al

392 increased PNNs may alter E/I balance contributing to decreased hippocampal sharp wave ripple events that negatively affect mood and memory <sup>91, 92</sup>. Increased expression of VAMP2 in subjects 393 with MDD is in line with preclinical evidence for glucocorticoid-mediated calcium influx increases 394 in hippocampal CA regions which perturbs plasticity, potentially resulting in poorer cognitive 395 396 performance <sup>93</sup>. Increased VAMP2 is also in agreement with evidence indicating altered synaptic markers in MDD <sup>94</sup>. Decreases in PNNs may result in reduced stabilization of synapses and 397 contribute to synaptic alterations, potentially resulting in memory impairment, memory 398 generalization, and cognitive deficits observed in MDD <sup>95</sup>. An extensive number of studies 399 implicate glial cell alterations in the pathology of depression (for review see <sup>96</sup>). In patients with 400 SUD/MDD, we observed decreased expression of Gfap. A similar nonsignificant trend for 401 decreased Gfap expression was observed in subjects with MDD. In our ANCOVA models, Gfap 402 403 expression was significantly affected by history of SSRI exposure, which was positively 404 associated with *Gfap* expression (Supplementary Figure 1B), suggesting that therapeutic effects of SSRIs may in part normalize Gfap levels. Our observed increase of Ctss gene expression may 405 represent a heightened inflammatory state in the hippocampus of subjects with MDD, which has 406 been extensively implicated in MDD <sup>97, 98</sup>, including in the hippocampus in a cohort that largely 407 408 overlaps with our cohort of subjects with MDD <sup>99</sup>.

# 409 TECHNICAL CONSIDERATIONS

Several factors represent challenges in examining molecular pathology in the brain of subjects with SUD, including polysubstance use, comorbidity with MDD, and pharmacological treatments. However, considering that this is representative of the real-world population of SUD it is important to examine the molecular pathology when these factors are present in the same subjects when considering development of therapeutic treatment strategies for this population. Our cohort consists of extensive information including retrospective clinical assessments, history of specific drugs of abuse and presence or absence of drugs of abuse and psychiatric medications in the

#### Valeri et al

417 blood at death from toxicology reports that can be accounted for using ANCOVA analyses, as conducted in our previous study using this same cohort <sup>43</sup>. Furthermore, the inclusion of samples 418 from rhesus monkeys with chronic alcohol use provides a valuable cause and effect comparison 419 for the most common drug of abuse in our human subjects. The development of additional 420 421 collections of NHP brain samples containing subjects self-administering specific drugs of abuse alone or in combination would further aide in interpreting human postmortem brain studies and 422 guiding strategies for novel treatment development. For our microscopy studies, use of WFA lectin 423 provides a standard view of a specific population of PNNs, as it binds to non-sulfated N-acetyl-D-424 galactosamine <sup>45</sup>. There are other populations of PNNs that can be detected with alternative 425 labeling methods which may surround complementary populations of neurons <sup>100</sup>. Future studies 426 with additional markers for PNN core proteins and sulfation motifs will provide insight into the 427 specific components of PNNs in SUD. Further, our fresh frozen postmortem tissue has inherent 428 429 technical limitations including lack of ability to conduct PVB-immunolabeling as well as reliable immunolabeling of synaptic markers, therefore mRNA measures were used for these markers. 430 Measurements of mRNA by qPCR do not identify the cell-types responsible for synthesis or 431 functional activity of any of the genes measured. 432

#### 433 CONCLUSIONS

In summary, our findings represent the first evidence for increased numerical densities of PNNs in the hippocampus of human subjects with SUD. Increased densities of hippocampal PNNs, together with decreased expression of ECM proteolytic genes and altered synaptic markers supports preclinical studies that suggest that PNNs may stabilize reward memories. Thus, PNNs and ECM molecules may represent promising targets for addressing cue-induced relapse in SUD. In comparison, subjects with MDD displayed generally opposite effects for many of the main outcome measures and subjects with SUD with a comorbid diagnosis of MDD

Valeri et al

suggesting that ECM changes in MDD oppose changes in SUD. These findings highlight the
 importance of considering comorbidities regarding SUD pathology and treatment strategies.

443

Funding: This work was funded by support from the National Institute of Mental Health (R01
MH125833 and R01 MH117460), the National Institute of Alcoholism and Alcohol Abuse (F31
AA030166 and R01 AA029023), and the Postmortem Brain Core of the Center for Psychiatric
Neuroscience, funded through an IDeA COBRE award from the National Institute of General
Medical Sciences (P30 GM103328).

**Acknowledgements:** The authors deeply appreciate the invaluable contributions made by the families consenting to donate brain tissue and be interviewed. We also gratefully acknowledge the support of the staff of the Cuyahoga County Medical Examiner's Office, Cleveland, Ohio. We acknowledge the expert assistance of Drs. James C. Overholser, George Jurjus, Lisa C. Konick, and of Lesa Dieter in establishing the psychiatric diagnoses, acquiring written consent and in collecting the tissues. For some of the subjects, the services of Timothy M. De Jong in acquiring written consent and Lisa Larkin and Nicole Herbst in tissue collection are gratefully acknowledged.

456 **Conflict of Interest Statement:** The authors have no competing financial interests to disclose.

457

**Data Availability Statement:** The data and original contributions presented in this study are included in the manuscript or supplemental materials. Further inquiries can be directed to the corresponding author.

461

462

463 **REFERENCES** 

464 465 466	1.	Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J <i>et al.</i> Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. <i>JAMA Psychiatry</i> 2016; <b>73</b> (1): 39-47.				
467 468 469 470	2.	SAMHSA. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. In: Services USDoHaH (ed). <u>www.samhsa.gov/data</u> , 2018.				
471 472 473	3.	Zironi I, Burattini C, Aicardi G, Janak PH. Context is a trigger for relapse to alcohol. <i>Behav Brain Res</i> 2006; <b>167</b> (1): 150-155.				
474 475 476	4.	Carter BL, Tiffany ST. Meta-analysis of cue-reactivity in addiction research. Addiction 1999; <b>94</b> (3): 327-340.				
477 478 479	5.	Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB. Relevance of cue reactivity to understanding alcohol and smoking relapse. <i>J Abnorm Psychol</i> 1988; <b>97</b> (2): 133-152.				
480 481 482	6.	Weiss F. Neurobiology of craving, conditioned reward and relapse. <i>Curr Opin Pharmacol</i> 2005; <b>5</b> (1): 9-19.				
483 484 485	7.	Janak PH, Chaudhri N. The Potent Effect of Environmental Context on Relapse to Alcohol-Seeking After Extinction. <i>Open Addict J</i> 2010; <b>3:</b> 76-87.				
486 487 488	8.	Xue YX, Xue LF, Liu JF, He J, Deng JH, Sun SC <i>et al.</i> Depletion of perineuronal nets in the amygdala to enhance the erasure of drug memories. <i>J Neurosci</i> 2014; <b>34</b> (19): 6647-6658.				
489 490 491 492	9.	Slaker M, Churchill L, Todd RP, Blacktop JM, Zuloaga DG, Raber J <i>et al.</i> Removal of perineuronal nets in the medial prefrontal cortex impairs the acquisition and reconsolidation of a cocaine-induced conditioned place preference memory. <i>J Neurosci</i> 2015; <b>35</b> (10): 4190-4202.				
493 494 495 496	10.	Brown TE, Forquer MR, Cocking DL, Jansen HT, Harding JW, Sorg BA. Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. <i>Learn Mem</i> 2007; <b>14</b> (3): 214-223.				
497 498 499 500	11.	Smith AW, Nealey KA, Wright JW, Walker BM. Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems. <i>Neurobiol Learn Mem</i> 2011; <b>96</b> (2): 199-206.				
501 502 503 504	12.	Seney ML, Kim SM, Glausier JR, Hildebrand MA, Xue X, Zong W <i>et al.</i> Transcriptional Alterations in Dorsolateral Prefrontal Cortex and Nucleus Accumbens Implicate Neuroinflammation and Synaptic Remodeling in Opioid Use Disorder. <i>Biol Psychiatry</i> 2021; <b>90</b> (8): 550-562.				

505 506 507 508	13.	Browne CJ, Futamura R, Minier-Toribio A, Hicks EM, Ramakrishnan A, Martínez-Rivera F <i>et al.</i> Transcriptional signatures of heroin intake and seeking throughout the brain reward circuit. <i>bioRxiv</i> 2023: 2023.2001.2011.523688.
509 510 511 512	14.	Chioma VC, Kruyer A, Bobadilla AC, Angelis A, Ellison Z, Hodebourg R <i>et al.</i> Heroin Seeking and Extinction From Seeking Activate Matrix Metalloproteinases at Synapses on Distinct Subpopulations of Accumbens Cells. <i>Biol Psychiatry</i> 2021; <b>89</b> (10): 947-958.
513 514 515 516	15.	Smith AC, Scofield MD, Kalivas PW. The tetrapartite synapse: Extracellular matrix remodeling contributes to corticoaccumbens plasticity underlying drug addiction. <i>Brain Res</i> 2015; <b>1628</b> (Pt A): 29-39.
517 518 519	16.	Slaker M, Blacktop JM, Sorg BA. Caught in the Net: Perineuronal Nets and Addiction. <i>Neural Plast</i> 2016; <b>2016</b> : 7538208.
520 521 522 523 524	17.	Roura-Martinez D, Diaz-Bejarano P, Ucha M, Paiva RR, Ambrosio E, Higuera-Matas A. Comparative analysis of the modulation of perineuronal nets in the prefrontal cortex of rats during protracted withdrawal from cocaine, heroin and sucrose self-administration. <i>Neuropharmacology</i> 2020; <b>180</b> : 108290.
525 526 527	18.	Valeri J, Gisabella B, Pantazopoulos H. Dynamic regulation of the extracellular matrix in reward memory processes: a question of time. <i>Frontiers in cellular neuroscience</i> 2023; <b>17:</b> 1208974.
528 529 530	19.	Ray MH, Williams BR, Kuppe MK, Bryant CD, Logan RW. A Glitch in the Matrix: The Role of Extracellular Matrix Remodeling in Opioid Use Disorder. <i>Front Integr Neurosci</i> 2022; <b>16:</b> 899637.
531 532 533 534	20.	Browne CJ, Futamura R, Minier-Toribio A, Hicks EM, Ramakrishnan A, Martinez-Rivera FJ <i>et al.</i> Transcriptional signatures of heroin intake and relapse throughout the brain reward circuitry in male mice. <i>Sci Adv</i> 2023; <b>9</b> (23): eadg8558.
535 536 537 538	21.	Vazquez-Sanroman DB, Monje RD, Bardo MT. Nicotine self-administration remodels perineuronal nets in ventral tegmental area and orbitofrontal cortex in adult male rats. <i>Addict Biol</i> 2017; <b>22</b> (6): 1743-1755.
539 540 541	22.	Fawcett JW, Fyhn M, Jendelova P, Kwok JCF, Ruzicka J, Sorg BA. The extracellular matrix and perineuronal nets in memory. <i>Mol Psychiatry</i> 2022; <b>27</b> (8): 3192-3203.
542 543 544	23.	Lasek AW, Chen H, Chen WY. Releasing Addiction Memories Trapped in Perineuronal Nets. <i>Trends Genet</i> 2018; <b>34</b> (3): 197-208.
545		

546 547	24.	Chen H, He D, Lasek AW. Repeated Binge Drinking Increases Perineuronal Nets in the Insular Cortex. Alcohol Clin Exp Res 2015; <b>39</b> (10): 1930-1938.
548 549 550	25.	Gogolla N, Caroni P, Luthi A, Herry C. Perineuronal nets protect fear memories from erasure. Science 2009; <b>325</b> (5945): 1258-1261.
551 552 553	26.	Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. <i>Science</i> 2002; <b>298</b> (5596): 1248-1251.
554 555 556 557	27.	Wright JW, Masino AJ, Reichert JR, Turner GD, Meighan SE, Meighan PC <i>et al.</i> Ethanol-induced impairment of spatial memory and brain matrix metalloproteinases. <i>Brain Res</i> 2003; <b>963</b> (1-2): 252-261.
558 559 560	28.	Natarajan R, Harding JW, Wright JW. A role for matrix metalloproteinases in nicotine-induced conditioned place preference and relapse in adolescent female rats. <i>J Exp Neurosci</i> 2013; <b>7:</b> 1-14.
561 562 563 564	29.	Smith AC, Kupchik YM, Scofield MD, Gipson CD, Wiggins A, Thomas CA <i>et al.</i> Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases. <i>Nat Neurosci</i> 2014; <b>17</b> (12): 1655-1657.
565 566 567 568	30.	Stefaniuk M, Beroun A, Lebitko T, Markina O, Leski S, Meyza K <i>et al.</i> Matrix Metalloproteinase-9 and Synaptic Plasticity in the Central Amygdala in Control of Alcohol-Seeking Behavior. <i>Biol Psychiatry</i> 2017; <b>81</b> (11): 907-917.
569 570 571 572	31.	Van den Oever MC, Lubbers BR, Goriounova NA, Li KW, Van der Schors RC, Loos M <i>et al.</i> Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking. <i>Neuropsychopharmacology</i> 2010; <b>35</b> (10): 2120-2133.
573 574 575 576	32.	Slaker ML, Jorgensen ET, Hegarty DM, Liu X, Kong Y, Zhang F <i>et al.</i> Cocaine Exposure Modulates Perineuronal Nets and Synaptic Excitability of Fast-Spiking Interneurons in the Medial Prefrontal Cortex. <i>eNeuro</i> 2018; <b>5</b> (5).
577 578 579	33.	Lasek AW. Effects of Ethanol on Brain Extracellular Matrix: Implications for Alcohol Use Disorder. <i>Alcohol Clin Exp Res</i> 2016; <b>40</b> (10): 2030-2042.
580 581 582	34.	Goode TD, Maren S. Common neurocircuitry mediating drug and fear relapse in preclinical models. <i>Psychopharmacology (Berl)</i> 2019; <b>236</b> (1): 415-437.
583 584 585 586	35.	Goldsmith SK, Joyce JN. Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase-immunoreactive fibers. <i>Hippocampus</i> 1994; <b>4</b> (3): 354-373.

Valeri et al

587 588 589 590 591	36.	Galvez-Marquez DK, Salgado-Menez M, Moreno-Castilla P, Rodriguez-Duran L, Escobar ML, Tecuapetla F <i>et al.</i> Spatial contextual recognition memory updating is modulated by dopamine release in the dorsal hippocampus from the locus coeruleus. <i>Proc Natl Acad Sci U S A</i> 2022; <b>119</b> (49): e2208254119.
592 593 594 595	37.	Krishnan S, Heer C, Cherian C, Sheffield MEJ. Reward expectation extinction restructures and degrades CA1 spatial maps through loss of a dopaminergic reward proximity signal. <i>Nature communications</i> 2022; <b>13</b> (1): 6662.
596 597 598 599	38.	Trouche S, Perestenko PV, van de Ven GM, Bratley CT, McNamara CG, Campo-Urriza N <i>et al.</i> Recoding a cocaine-place memory engram to a neutral engram in the hippocampus. <i>Nat Neurosci</i> 2016; <b>19</b> (4): 564-567.
600 601 602 603	39.	Wingert JC, Sorg BA. Impact of Perineuronal Nets on Electrophysiology of Parvalbumin Interneurons, Principal Neurons, and Brain Oscillations: A Review. <i>Front Synaptic Neurosci</i> 2021; <b>13:</b> 673210.
604 605 606 607	40.	Frischknecht R, Heine M, Perrais D, Seidenbecher CI, Choquet D, Gundelfinger ED. Brain extracellular matrix affects AMPA receptor lateral mobility and short-term synaptic plasticity. <i>Nat Neurosci</i> 2009; <b>12</b> (7): 897-904.
608 609 610	41.	Shah A, Lodge DJ. A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia. <i>Transl Psychiatry</i> 2013; <b>3</b> (1): e215.
611 612 613 614	42.	Mueller TI, Lavori PW, Keller MB, Swartz A, Warshaw M, Hasin D <i>et al.</i> Prognostic effect of the variable course of alcoholism on the 10-year course of depression. <i>Am J Psychiatry</i> 1994; <b>151</b> (5): 701-706.
615 616 617 618	43.	Valeri J, O'Donovan SM, Wang W, Sinclair D, Bollavarapu R, Gisabella B <i>et al.</i> Altered expression of somatostatin signaling molecules and clock genes in the hippocampus of subjects with substance use disorder. <i>Front Neurosci</i> 2022; <b>16</b> : 903941.
619 620 621	44.	Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H <i>et al</i> . Hippocampal interneurons are abnormal in schizophrenia. <i>Schizophr Res</i> 2011; <b>131</b> (1-3): 165-173.
622 623 624 625	45.	Nadanaka S, Miyata S, Yaqiang B, Tamura JI, Habuchi O, Kitagawa H. Reconsideration of the Semaphorin-3A Binding Motif Found in Chondroitin Sulfate Using Galnac4s-6st-Knockout Mice. <i>Biomolecules</i> 2020; <b>10</b> (11).
626		

Valeri et al

- 627 Pantazopoulos H, Murray EA, Berretta S. Total number, distribution, and phenotype of cells 46. 628 expressing chondroitin sulfate proteoglycans in the normal human amygdala. Brain Res 2008; 629 **1207:** 84-95. 630 631 47. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in 632 the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry 633 2010; **67**(2): 155-166. 634 635 48. O'Donovan SM, Sullivan C, Koene R, Devine E, Hasselfeld K, Moody CL et al. Cell-subtype-specific 636 changes in adenosine pathways in schizophrenia. Neuropsychopharmacology 2018; 43(8): 1667-637 1674. 638 639 49. Pantazopoulos H, Sawyer C, Heckers S, Berretta S, Markota M. Chondroitin Sulfate Proteoglycan Abnormalities in the Hippocampus of Subjects with Schizophrenia. *Neuropsychopharmacology* 640 641 2014; **39:** S298-S299. 642 643 50. Yamada J, Jinno S. Spatio-temporal differences in perineuronal net expression in the mouse 644 hippocampus, with reference to parvalbumin. Neuroscience 2013; 253: 368-379. 645 Rogers SL, Rankin-Gee E, Risbud RM, Porter BE, Marsh ED. Normal Development of the 646 51. Perineuronal Net in Humans; In Patients with and without Epilepsy. Neuroscience 2018; 384: 350-647 648 360. 649 52. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in 650 651 the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Archives of general psychiatry 2010; 67(2): 155-166. 652 653 Yan C, Jiang J, Yang Y, Geng X, Dong W. The function of VAMP2 in mediating membrane fusion: 654 53. 655 An overview. Frontiers in Molecular Neuroscience 2022; 15. 656 657 54. Torres VI, Vallejo D, Inestrosa NC. Emerging Synaptic Molecules as Candidates in the Etiology of 658 Neurological Disorders. Neural Plast 2017; 2017: 8081758. 659 55. Neuhofer D, Kalivas P. Metaplasticity at the addicted tetrapartite synapse: A common 660 denominator of drug induced adaptations and potential treatment target for addiction. 661 662 Neurobiology of Learning and Memory 2018; 154: 97-111.
- 66456.Gonzalez AE, Jorgensen ET, Ramos JD, Harkness JH, Aadland JA, Brown TE *et al.* Impact of665Perineuronal Net Removal in the Rat Medial Prefrontal Cortex on Parvalbumin Interneurons After666Reinstatement of Cocaine Conditioned Place Preference. Front Cell Neurosci 2022; 16: 932391.

667

668 669 670	57.	Jorgensen ET, Gonzalez AE, Harkness JH, Hegarty DM, Thakar A, Burchi DJ <i>et al</i> . Cocaine memory reactivation induces functional adaptations within parvalbumin interneurons in the rat medial prefrontal cortex. <i>Addict Biol</i> 2021; <b>26</b> (3): e12947.
671 672 673	58.	Blacktop JM, Sorg BA. Perineuronal nets in the lateral hypothalamus area regulate cue-induced reinstatement of cocaine-seeking behavior. <i>Neuropsychopharmacology</i> 2019; <b>44</b> (5): 850-858.
674 675 676 677	59.	Guarque-Chabrera J, Sanchez-Hernandez A, Ibanez-Marin P, Melchor-Eixea I, Miquel M. Role of Perineuronal nets in the cerebellar cortex in cocaine-induced conditioned preference, extinction, and reinstatement. <i>Neuropharmacology</i> 2022; <b>218:</b> 109210.
678 679 680	60.	Vazquez-Sanroman D, Leto K, Cerezo-Garcia M, Carbo-Gas M, Sanchis-Segura C, Carulli D <i>et al.</i> The cerebellum on cocaine: plasticity and metaplasticity. <i>Addict Biol</i> 2015; <b>20</b> (5): 941-955.
681 682 683	61.	Kalb RG, Hockfield S. Molecular evidence for early activity-dependent development of hamster motor neurons. <i>J Neurosci</i> 1988; <b>8</b> (7): 2350-2360.
684 685 686 687	62.	Sugiyama S, Di Nardo AA, Aizawa S, Matsuo I, Volovitch M, Prochiantz A <i>et al</i> . Experience- dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity. <i>Cell</i> 2008; <b>134</b> (3): 508-520.
688 689 690	63.	Frischknecht R, Gundelfinger ED. The brain's extracellular matrix and its role in synaptic plasticity. <i>Adv Exp Med Biol</i> 2012; <b>970:</b> 153-171.
691 692 693	64.	Dityatev A, Schachner M, Sonderegger P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. <i>Nat Rev Neurosci</i> 2010; <b>11</b> (11): 735-746.
694 695 696	65.	Gundelfinger ED, Frischknecht R, Choquet D, Heine M. Converting juvenile into adult plasticity: a role for the brain's extracellular matrix. <i>Eur J Neurosci</i> 2010; <b>31</b> (12): 2156-2165.
697 698 699 700	66.	Cabungcal JH, Steullet P, Morishita H, Kraftsik R, Cuenod M, Hensch TK <i>et al.</i> Perineuronal nets protect fast-spiking interneurons against oxidative stress. <i>Proc Natl Acad Sci U S A</i> 2013; <b>110</b> (22): 9130-9135.
701 702 703	67.	Morawski M, Bruckner MK, Riederer P, Bruckner G, Arendt T. Perineuronal nets potentially protect against oxidative stress. <i>Exp Neurol</i> 2004; <b>188</b> (2): 309-315.
704 705 706	68.	Trifilieff P, Martinez D. Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. <i>Neuropharmacology</i> 2014; <b>76 Pt B</b> (0 0): 498-509.
707		

708 709 710	69.	Li JN, Liu XL, Li L. Prefrontal GABA and glutamate levels correlate with impulsivity and cognitive function of prescription opioid addicts: A (1) H-magnetic resonance spectroscopy study. <i>Psychiatry Clin Neurosci</i> 2020; <b>74</b> (1): 77-83.
711 712 713	70.	D'Souza MS, Markou A. The "stop" and "go" of nicotine dependence: role of GABA and glutamate. <i>Cold Spring Harb Perspect Med</i> 2013; <b>3</b> (6).
714 715	71.	Balmer TS. Perineuronal Nets Enhance the Excitability of Fast-Spiking Neurons. <i>eNeuro</i> 2016; <b>3</b> (4).
716 717 718 719	72.	Steullet P, Cabungcal JH, Bukhari SA, Ardelt MI, Pantazopoulos H, Hamati F <i>et al</i> . The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress. <i>Mol Psychiatry</i> 2017.
720 721 722 723	73.	Pantazopoulos H, Woo T-UW, Lim MP, Lange N, Berretta S. Extracellular Matrix-Glial Abnormalities in the Amygdala and Entorhinal Cortex of Subjects Diagnosed With Schizophrenia. <i>Arch Gen Psychiatry</i> 2010; <b>67</b> (2): 155-166.
724 725 726 727	74.	Pantazopoulos H, Lange N, Hassinger L, Berretta S. Subpopulations of neurons expressing parvalbumin in the human amygdala. <i>The Journal of comparative neurology</i> 2006; <b>496</b> (5): 706-722.
728 729 730 731	75.	Espinoza C, Guzman SJ, Zhang X, Jonas P. Parvalbumin+ interneurons obey unique connectivity rules and establish a powerful lateral-inhibition microcircuit in dentate gyrus. <i>Nature Communications</i> 2018; <b>9</b> (1): 4605.
732 733 734 735	76.	Udakis M, Pedrosa V, Chamberlain SEL, Clopath C, Mellor JR. Interneuron-specific plasticity at parvalbumin and somatostatin inhibitory synapses onto CA1 pyramidal neurons shapes hippocampal output. <i>Nature Communications</i> 2020; <b>11</b> (1): 4395.
736 737 738	77.	Yamada J, Ohgomori T, Jinno S. Perineuronal nets affect parvalbumin expression in GABAergic neurons of the mouse hippocampus. <i>Eur J Neurosci</i> 2015; <b>41</b> (3): 368-378.
739 740 741 742	78.	Lesnikova A, Casarotto PC, Fred SM, Voipio M, Winkel F, Steinzeig A <i>et al.</i> Chondroitinase and Antidepressants Promote Plasticity by Releasing TRKB from Dephosphorylating Control of PTPo in Parvalbumin Neurons. <i>J Neurosci</i> 2021; <b>41</b> (5): 972-980.
743 744 745 746	79.	Brown TE, Sorg BA. Net gain and loss: influence of natural rewards and drugs of abuse on perineuronal nets. <i>Neuropsychopharmacology</i> 2023; <b>48</b> (1): 3-20.
740		

Valeri et al

747 80. Huang YY, Kandel ER. D1/D5 receptor agonists induce a protein synthesis-dependent late 748 potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci U S A 1995; 92(7): 2446-749 2450. 750 751 81. Gasbarri A, Packard MG, Campana E, Pacitti C. Anterograde and retrograde tracing of projections 752 from the ventral tegmental area to the hippocampal formation in the rat. Brain Res Bull 1994; 753 **33**(4): 445-452. 754 755 82. Yin LT, Xie XY, Xue LY, Yang XR, Jia J, Zhang Y et al. Matrix Metalloproteinase-9 Overexpression 756 Regulates Hippocampal Synaptic Plasticity and Decreases Alcohol Consumption and Preference in 757 Mice. Neurochem Res 2020; 45(8): 1902-1912. 758 759 83. Samochowiec A, Grzywacz A, Kaczmarek L, Bienkowski P, Samochowiec J, Mierzejewski P et al. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: 760 761 family and case control study. Brain Res 2010; 1327: 103-106. 762 763 84. Eichenbaum H. Prefrontal-hippocampal interactions in episodic memory. Nature Reviews 764 Neuroscience 2017; 18(9): 547-558. 765 766 85. Goodman J, Packard MG. Memory Systems and the Addicted Brain. Frontiers in Psychiatry 2016; 767 7. 768 769 86. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: 770 a self-medication hypothesis. Neuropsychopharmacology 1998; 18(3): 135-174. 771 87. Gilman SE, Abraham HD. A longitudinal study of the order of onset of alcohol dependence and 772 773 major depression. Drug Alcohol Depend 2001; 63(3): 277-286. 774 775 88. Young MA, Fogg LF, Scheftner WA, Fawcett JA. Interactions of risk factors in predicting suicide. 776 Am J Psychiatry 1994; 151(3): 434-435. 777 778 89. Roughley PJ, Mort JS. The role of aggrecan in normal and osteoarthritic cartilage. Journal of 779 Experimental Orthopaedics 2014; 1(1): 8. 780 90. Riga D, Kramvis I, Koskinen MK, van Bokhoven P, van der Harst JE, Heistek TS et al. Hippocampal 781 782 extracellular matrix alterations contribute to cognitive impairment associated with a chronic 783 depressive-like state in rats. Sci Transl Med 2017; 9(421). 784 Blanco I, Conant K. Extracellular matrix remodeling with stress and depression: Studies in human, 785 91. 786 rodent and zebrafish models. Eur J Neurosci 2021; 53(12): 3879-3888. 787

788 789	92.	Sun ZY, Bozzelli PL, Caccavano A, Allen M, Balmuth J, Vicini S <i>et al.</i> Disruption of perineuronal nets increases the frequency of sharp wave ripple events. <i>Hippocampus</i> 2018; <b>28</b> (1): 42-52.
790 791 792	93.	Karst H, Joëls M. Corticosterone Slowly Enhances Miniature Excitatory Postsynaptic Current Amplitude in Mice CA1 Hippocampal Cells. <i>Journal of Neurophysiology</i> 2005; <b>94</b> (5): 3479-3486.
793 794 795 796	94.	Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC <i>et al.</i> Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. <i>Int J Neuropsychopharmacol</i> 2013; <b>16</b> (1): 69-82.
797 798 799 800	95.	Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. <i>Neuropsychiatr Dis Treat</i> 2019; <b>15:</b> 1249-1258.
801 802 803	96.	Miguel-Hidalgo JJ. Astrocytes as Context for the Involvement of Myelin and Nodes of Ranvier in the Pathophysiology of Depression and Stress-Related Disorders. <i>J Psychiatr Brain Sci</i> 2023; <b>8</b> .
804 805 806 807	97.	Kohler-Forsberg O, C NL, Hjorthoj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti- inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. <i>Acta psychiatrica Scandinavica</i> 2019; <b>139</b> (5): 404-419.
808 809 810	98.	Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. <i>Mol Psychiatry</i> 2023; <b>28</b> (1): 284-297.
811 812 813 814	99.	Mahajan GJ, Vallender EJ, Garrett MR, Challagundla L, Overholser JC, Jurjus G <i>et al.</i> Altered neuro- inflammatory gene expression in hippocampus in major depressive disorder. <i>Prog</i> <i>Neuropsychopharmacol Biol Psychiatry</i> 2018; <b>82:</b> 177-186.
815 816 817	100.	Scarlett JM, Hu SJ, Alonge KM. The "Loss" of Perineuronal Nets in Alzheimer's Disease: Missing or Hiding in Plain Sight? <i>Front Integr Neurosci</i> 2022; <b>16:</b> 896400.
818		
819		
820		
821		
822		
823		

Valeri et al


				874		
Cohort A:		cts for SUD, S	SUD/MDD, a	nd MDD		
		analyses				
	SUD	SUD/MDD	MDD	Control		
	n=20	n=24	n=20	n=20		
Age, Years	34.8±9.0	43.9±11.1	47±11.4	43.2±11.42		
Sex						
Male	17	16	14	13		
Female	3	8	6	7		
Race						
White	13	20	17	11		
Black	7	4	3	9		
Brain pH	6.57±0.23	6.54±0.27	6.5±0.32	6.5±0.25		
PMI, Hours	18.58±8.5	20.2±7.6	23.7±5.9	21.2±6.8		
Cohort B: PFA	fixed sample	es from contro	ol subjects	for labeling		
0	f synaptic ma	rkers and PV				
Age		43.0±2				
Sex	2 Male, 1 Female					
	Hemisphere 2 Right, 1 Left					
Cohort C: Rhesus macaque subjects						
		drinkers -7	Control n=5			
Age, Years	Age, Years 7.20±0.04			6.90±0.49		
Sex	Male (n=7)		Male (n=5)			
BAC, mg pct		±12.76	NA			

840

Table 1. Basic cohort demographic information for both human and rhesus macaque subjects.
Abbreviations: SUD, substance use disorder; MDD, major depressive disorder; PFA:
Paraformaldehyde; PMI, postmortem interval, BAC, blood alcohol concentration, 12-month average. Values represent mean ± SEM.

845

# Valeri et al



847

Figure 1. Altered PNNs in SUD and MDD. (A and B) Representative low-magnification 848 photomicrographs of CA1 SO PNNs labeled by WFA, scalebars = 0.5 mm. (C and D) High-849 magnification photomicrographs of WFA-labeled CA1 SO PNNs, scalebars = 50  $\mu$ m. (E) 850 Diagnostic group comparisons of PNN densities in CA1 stratum oriens. Subjects with SUD had 851 significantly increased densities of PNNs (p < 0.007; adjusted for significant effects of cocaine 852 history and PMI) whereas subjects with MDD displayed significantly reduced PNN densities (p < 1853 854 0.05; adjusted for significant effects of sex and calcium channel blockers). No significant effects 855 were found in the comorbid SUD and MDD group. (F) Diagnostic group comparisons of normalized hippocampal Pvb gene expression, with a gradient increase between SUD (p < 0.007; 856 adjusted for significant effects of cocaine in the toxicology report), SUD/MDD (p < 0.008; adjusted 857 for significant effects of MDD duration), and MDD (p < 0.005). (G) Representative PNN 858 quantification overlays of hippocampi from subjects within diagnostic groups. (H and I) 859 860 Representative low-magnification photomicrographs of CA4 WFA-labeled glia, scalebars = 0.5 mm. (J and K) Representative high-magnification WFA-labeled glia, scalebars = 80 50 µm. (L) 861 Numerical density measurements of CA4 WFA-labeled glial cells in subjects with SUD, MDD, and 862 SUD/MDD. (M) Normalized gene expression of Gfap was significantly decreased in subjects with 863 comorbid SUD and MDD (p < 0.02; adjusted for significant effects of antidepressant history), but 864 unaffected in either isolated disorder. (N) Representative WFA+ glia quantification overlays of 865 866 hippocampi from subjects within diagnostic groups. Error bars are mean ± SEM.

867

868

# Valeri et al






Figure 2. Gene expression of the excitatory synaptic marker Vamp2 is altered in SUD and MDD. 871 (A) Gene expression of the presynaptic vesicle marker Vamp2 is increased in both SUD and 872 MDD, but not in the comorbid condition. (B-E) Multiplex immunofluorescent imaging of VAMP2 873 immunoreactive puncta within a PNN and on the surface of a PVB interneuron. (B) WFA-labeled 874 PNN (green), (C) PVB interneuron (blue) and VAMP2 synaptic puncta (red) and spatial overlap 875 (yellow) (arrows indicate overlap). (D) Composite z-projection of WFA, PVB, and VAMP2. (E) 876 Zoomed inset of 1D, with arrows denoting spatial overlap of VAMP2 with WFA (yellow puncta). 877 (F) There were no significant changes in transcription of the synaptic marker Syn1 in any of the 878 diagnostic groups. (G-J) Multiplex immunofluorescent imaging depicting SYN1 labeling within a 879 880 PNN surrounding a PVB interneuron. (G) WFA-labeled PNN (green), (H) PVB neuron (blue) and SYN1 (red), (I) composite z-projection of all three channels. (J) Zoomed inset depicts spatial 881 overlap with of SYN1 puncta with WFA labeling (arrows to yellow puncta). All scalebars are 10 882 883  $\mu$ m. Error bars are mean  $\pm$  SEM.

## Valeri et al






Figure 3. Gene expression of ECM biosynthetic and regulatory molecules in SUD and MDD. (A) 886 887 Gene expression of the ECM proteolytic molecule Mmp9 was significantly decreased in subjects with SUD compared to controls (p < 0.05), but no significant differences were detected in the 888 other two diagnostic groups. (B) Analysis of covariance uncovered significantly decreased mRNA 889 levels of cathepsin S in subjects with SUD (p < 0.03; adjusted for significant effects of cocaine in 890 the toxicology report). Subjects with MDD had significantly increased expression of cathepsin S 891 892 compared to controls (p < 0.03; adjusted for significant effects of alcohol history and ZT time of death). (C) Gene expression of the CSPG aggrecan was significantly increased in subjects with 893 894 comorbid SUD and MDD (p < 0.03) but was unaffected in either condition separately. (D) Gene expression of the CSPG biosynthetic molecule Chsv1 was significantly increased in subjects with 895 SUD (p < 0.05; adjusted for significant effects of tissue pH) and in subjects with comorbid SUD 896 and MDD (p < 0.0001; adjusted for significant effects of tissue pH and duration of AUD), while 897 898 patients with MDD did not meet significance in any direction. Error bars are mean ± SEM.

899

# Valeri et al






900

Figure 4. Chronic alcohol self-administration increases PNN densities throughout the 901 hippocampus of rhesus monkeys. Abbreviations: DG GCL, granule cell layer of the dentate gyrus; 902 903 SLM, stratum lacunosum moleculare; SGZ, subgranular zone; CA, cornu ammonis; SO, stratum oriens; SP, stratum pyramidale. (A) Representative microscopy of PNNs labeled with WFA in CA1 904 SO, scalebar = 50  $\mu$ m. (B) Inset of Figure 4A at high-magnification, scalebar = 30  $\mu$ m. (C) 905 Representative microscopy of a WFA-labeled glial cell proximal to the DG GCL, scalebar = 50 906 μm. (D) Inset of Figure 4C at 40× magnification, scalebar = 50 μm. (E) Comparisons of PNN 907 densities throughout the hippocampus between control (white bars) and monkeys with chronic 908 909 alcohol self-administration (red bars). (F) Comparison of WFA-glia densities in the DG GCL and 910 DG SLM between control and monkeys with chronic alcohol self-administration. (G) Comparison 911 of WFA-glia densities in the SGZ and CA nuclei of the hippocampus between control and monkeys 912 with chronic alcohol self-administration.

- 913
- 914
- 915
- 916
- -
- 917

# Valeri et al



918

**Figure 5.** Summary diagram of proposed ECM and synaptic alterations in the hippocampus of subjects with SUD with or without comorbid MDD. Panels providing visual depictions of pathological observations from the present study. Numbers of arrows describe the intensity of changes compared to the other diagnostic groups, and a key is provided within the control panel to characterize the graphics used within the figure. Created with BioRender.com.

924